UNSPSC 51281664: Ribostamycin sulfate

This classification denotes an aminoglycoside antibiotic C17H34N4O10.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QFN1QU7PEN, chemically known as o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(.beta-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine sulfate, but more generally known as ribostamycin sulfate, which bears US NIH Compound Identifier 5702279. European Medicines Agency schedules in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04244MIG.

UNSPSC 51281664 Ribostamycin sulfate is a Commodity code that shows a mismatch between its nominal scope and recent state and local procurement activity. The code's name references a specific aminoglycoside antibiotic, but the four most recent opportunities tagged under it—spanning county health departments, state health agencies, municipal fire departments, and multistate cooperative purchasing—are soliciting naloxone, opioid overdose reversal agents, emergency medical supplies, and generic pharmaceutical and OTC products through various competitive mechanisms including IFB, RFI, and RFP. The actual procurement pattern reflects state and local demand for emergency response medications, pharmacy benefit program administration, and medical supply fulfillment rather than ribostamycin sulfate itself.

Recent activity shows issuing bodies across multiple governance tiers: Seminole County, Florida (county-level health) posted an IFB on June 30, 2026, for naloxone and drug deactivation systems; the City of Tampa's Purchasing Department released an ITB on March 25, 2026, for medical and first aid supplies estimated at $700,000 and designated as sheltered market for certified Small Local Business Enterprises with a 5% bid discount; the Texas Health and Human Services Commission issued an RFI on April 3, 2026, exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local jurisdictions, with proposals due March 26, 2026. The MMCAP solicitation requires vendor compliance with cGMP, DSCSA, and FDA requirements, maintenance of relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, and a 3% administrative fee structure. Geographic activity includes Florida, Texas, Minnesota, and Oregon, with the MMCAP vehicle serving multiple states. The code shows little relevant procurement activity for ribostamycin sulfate as a discrete product line.